Insta
CSIR Identifies 25 Drugs For Repurposing Against Covid-19, Favipiravir Emerges As Most Promising One
CSIR Logo (Pic Via Facebook)
The Council of Scientific and Industrial Research (CSIR) has identified the top 25 drugs/drug candidates for repurposing them for the treatment of Covid-19 patients in India.
The repurposed drugs can be quickly deployed for treatment as opposed to new drugs which need almost a decade of development.
“CSIR has identified the top 25 drugs/drug candidates for repurposing. Among these top 25 drugs, Favipiravir a broad-spectrum inhibitor of viral RNA polymerase has emerged as of one of the most promising drugs,” the Ministry of Science and Technology said in a release.
Favipiravir was developed by Fujifilm Toyama Chemical Ltd, and is an approved treatment for common influenza and is marketed in Russia, China and Japan, it added.
Cipla will be conducting the investigations prior to launching on this drug against Covid-19 in India. For this purpose, the company has approached the Drug Controller General of India (DCGI) for approval to launch Favipiravir in India.
Favipiravir is a generic drug and already being used for the treatment of influenza and also is in clinical trials for Covid-19 in many countries such as in China, Japan and Italy.
“Under the auspices of ICMR, Cipla will conduct a suitable limited trial prior to marketing the product as Ciplenza,” the release added.
Introducing ElectionsHQ + 50 Ground Reports Project
The 2024 elections might seem easy to guess, but there are some important questions that shouldn't be missed.
Do freebies still sway voters? Do people prioritise infrastructure when voting? How will Punjab vote?
The answers to these questions provide great insights into where we, as a country, are headed in the years to come.
Swarajya is starting a project with an aim to do 50 solid ground stories and a smart commentary service on WhatsApp, a one-of-a-kind. We'd love your support during this election season.
Click below to contribute.
Latest
